Efficacy of penguin cap as scalp cooling system for prevention of alopecia in patients undergoing chemotherapy

Kargar, Marzieh; Sarvestani, Raheleh Sabet; Khojasteh, Habib Noorani; Heidari, Mohammad Taghi

doi:10.1111/j.1365-2648.2011.05668.x

Cited by 25 publications

(35 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alopecia is one of the well established and distressing adverse effects of cancer chemotherapy which occurs due to the misidentification and suppression of rapidly growing hair follicular cell growth by these chemotherapeutics (Kargar et al, 2011). In corroboration with that, in our study also CHOP chemotherapy caused upto grade 2 alopecia in 32% of the subjects and grade 1 alopecia in 20% of the patients (Figure 7).…”

Section: Resultssupporting

confidence: 78%

A supplementary report on the toxic manifestations of CHOP regimen in subjects with intermediate grade NHL

Remesh

2012

Int Curr Pharm J

View full text Add to dashboard Cite

Cancer chemotherapy engenders a gamut of unpredictable and perilous toxicities, which can cause substantialmortality, morbidity, and results in escalated healthcare costs due to increased requirement for ameliorative treat-ments and toxicity-related hospitalization. The main objective of this article is to report a range of adverse effects ofCHOP regimen in patients with intermediate grade Non-Hodgkins Lymphoma (NHL). This randomized prospective study was conducted on de novo intermediate grade NHL patients, aged >20?60 years, receiving CHOP chemotherapyregimen. Out of 30 patients who satisfied the inclusion criteria, only 25 patients completed 6 cycles of chemotherapy and were evaluated for various toxicities. Evaluation of all the 25 subjects showed that, in comparison with the baseline, most patients exhibited toxic damages. The hepatopancreatic, dermatological, vascular and nephrologicaldamages, eventually resulted in weight loss, hepatomegaly, alopecia, hypotension, as well as abnormal levels of serum liver markers, serum creatinine and blood glucose. But, the necessity to interrupt the CHOP treatment did not arise in any of the patients. Thus, in this study combination chemotherapy with CHOP protocol was well tolerated by majority of the subjects.DOI: http://dx.doi.org/10.3329/icpj.v1i10.11850 International Current Pharmaceutical Journal 2012, 1(10): 322-327

show abstract

Section: Resultssupporting

confidence: 78%

A supplementary report on the toxic manifestations of CHOP regimen in subjects with intermediate grade NHL

Remesh

2012

Int Curr Pharm J

View full text Add to dashboard Cite

show abstract

“…Fourteen studies were excluded for the following reasons: No follow-up or unclear follow-up time following completion of chemotherapy (total of 10) [21–30]; patients used scalp cooling for treatment of metastatic disease (total of 2) [31, 32]; treatment for breast cancer was not specified (one study) [33]; and one study was excluded due to unclear cancer type at presentation [34] (Table 2). …”

Section: Resultsmentioning

confidence: 99%

“…However, there was no mention of the follow-up time in this patient cohort. Scalp cooling was employedDean [24]Fifty-eight breast cancer patients treated with doxorubicin and with scalp cooling were reported on for scalp metastasis, but there was no mention of the follow-up timeJohansen [31]One patient in scalp cooling group who already had metastatic breast cancer (in the liver) experienced scalp metastasis ( n = 61); all patients in group already had metastatic primary or recurrent cancer originating from the breastKargar [34]Unclear as to type of primary cancer patients hadLemenager [32]Breast cancer patients treated with chemotherapy ( n = 88); all had metastatic disease and were treated with scalp hypothermia. No mention of scalp metastasisLookingbill [33]No mention of how patients with breast cancer were treated; There were 18 patients with scalp metastases out of 707 primary breast cancer patients.…”

Section: Resultsmentioning

confidence: 99%

Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis

Rugo

Melin

Voigt³

2017

Breast Cancer Res Treat

View full text Add to dashboard Cite

PurposeThe risk of scalp metastases in patients using scalp cooling for preservation of hair during chemotherapy has been a concern but is poorly described.MethodsA systematic review and meta-analysis of longitudinal studies was undertaken to evaluate the effect of scalp cooling versus no scalp cooling on the risk of scalp metastasis in patients treated for breast cancer with chemotherapy. Electronic databases, journal specific, and hand searches of articles identified were searched. Patients were matched based on disease, treatment, lack of metastatic disease, and sex.ResultsA total of 24 full-text articles were identified for review. Of these articles, ten quantified the incidence of scalp metastasis with scalp cooling over time. For scalp cooling, 1959 patients were evaluated over an estimated mean time frame of 43.1 months. For no scalp cooling, 1238 patients were evaluated over an estimated mean time frame of 87.4 months. The incidence rate of scalp metastasis in the scalp cooling group versus the no scalp cooling group was 0.61% (95% CI 0.32–1.1%) versus 0.41% (95% CI 0.13–0.94%); P = 0.43.ConclusionThe incidence of scalp metastases was low regardless of scalp cooling. This analysis suggests that scalp cooling does not increase the incidence of scalp metastases.Electronic supplementary materialThe online version of this article (doi:10.1007/s10549-017-4185-9) contains supplementary material, which is available to authorized users.

show abstract

“…For example, many patients show signs of distress when they are anticipating and experiencing alopecia. 72 The nurse can implement the efficacy enhancing intervention of vicarious experience and social persuasion by referring the patient to cancer survivor support groups and relaying experiences with patients who have undergone distress from alopecia. For instance, a nurse could refer a patient who is experiencing alopecia to a cancer survivor hair and make-up appointment to demonstrate what the patient can do to offset the change in his or her appearance.…”

Section: Implications For Practice and Researchmentioning

confidence: 99%

Enhancing Self-efficacy for Optimized Patient Outcomes Through the Theory of Symptom Self-management

Hoffman¹

2013

Cancer Nursing

159

113

View full text Add to dashboard Cite

Background In today’s world, greater patient empowerment is imperative since 90 million Americans live with one or more chronic conditions such as cancer. Evidence reveals that healthy behaviors such as effective symptom self-management can prevent or reduce much of the suffering from cancer. Oncology nurses play a pivotal role in developing a symptom self-management plan that is critical to optimizing a patient’s symptom self-management behaviors. Objective This article uses exemplars to describe how oncology nurses can apply a tested middle-range theory, the Theory of Symptom Self-Management, to clinical practice by incorporating interventions to increase a patient’s perceived self-efficacy to optimize patient outcomes. Methods The Theory of Symptom Self-Management provides a means to understand the dynamic aspects of symptom self-management and provides a tested framework for the development of efficacy enhancing interventions for use by oncology nurses in clinical practice. Results Exemplars based on the Theory of Symptom Self-Management that depict how oncology nursing can use perceived self-efficacy enhancing symptom self-management interventions to improve the functional status and quality of life of their patients. Conclusion Guided by a theoretical approach, oncology nurses can have a significant positive impact on the lives of their patients by reducing the symptom burden associated with cancer and its treatment. Implications for Practice Oncology nurses can partner with their patients to design tailored approaches to symptom self-management. These tailored approaches provide the ability to implement patient specific behaviors that recognize, prevent, relieve, or decrease the timing, intensity, distress, concurrence, and unpleasant quality of symptoms.

show abstract

Efficacy of penguin cap as scalp cooling system for prevention of alopecia in patients undergoing chemotherapy

Abstract: A penguin cap can be an effective method to avoid alopecia in patients receiving chemotherapy drugs. However, it is important to bear in mind that because of individual characteristics, liver function and drug regimens it is not successful in all cases.

Cited by 25 publications

References 6 publications

A supplementary report on the toxic manifestations of CHOP regimen in subjects with intermediate grade NHL

A supplementary report on the toxic manifestations of CHOP regimen in subjects with intermediate grade NHL

Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis

Enhancing Self-efficacy for Optimized Patient Outcomes Through the Theory of Symptom Self-management

Contact Info

Product

Resources

About